www.carricktherapeutics.com Open in urlscan Pro
185.161.17.76  Public Scan

Submitted URL: http://www.carricktherapeutics.com/
Effective URL: https://www.carricktherapeutics.com/
Submission: On December 16 via api from US — Scanned from GB

Form analysis 1 forms found in the DOM

GET https://www.carricktherapeutics.com/

<form role="search" method="get" class="et-search-form" action="https://www.carricktherapeutics.com/">
  <input type="search" class="et-search-field" placeholder="Search …" value="" name="s" title="Search for:">
</form>

Text Content

 * Home
 * Science
   * Pipeline
 * People
 * Partnering
 * Careers
 * Press
 * Privacy

Select Page
 * Home
 * Science
   * Pipeline
 * People
 * Partnering
 * Careers
 * Press
 * Privacy


Video Player
00:00
00:00
00:30
Use Up/Down Arrow keys to increase or decrease volume.







TARGETING AGGRESSIVE CANCER

Transforming cancer treatments and the lives of cancer patients by targeting the
molecular pathways that drive the most aggressive and resistant forms of cancer.


OUR VISION

Carrick Therapeutics is building an innovative portfolio of first-in-class
treatments that target multiple mechanisms of the most aggressive forms of
cancer. In doing so, we aim to have a major impact on the lives of patients with
the greatest unmet need and transform the way that cancer is treated.


OUR FOCUS

Our programmes are advanced through understanding the mechanisms that cause
cancer and resistance allied with cutting-edge technologies to identify
therapeutics and those who would most benefit from them. Through linking a
network of clinicians and scientists in internationally leading research
institutes and hospitals, Carrick Therapeutics will drive its portfolio of
ground-breaking cancer therapies from laboratory to clinic.


OUR TEAM

A highly experienced and dedicated team with an outstanding track record of
discovering and developing innovative cancer medicines; changing the treatment
options for patients from non-selective chemotherapy to better tolerated
targeted agents. The Carrick Therapeutics team have many examples of successful
launches and commercial success and of strategies to target the right drug to
the right patient.


OUR COLLABORATORS

Our network of collaborating cancer experts include the world’s leading cancer
research charity, Cancer Research UK, and pioneering researchers from several of
the world’s top universities, including Cambridge, Imperial College London and
Oxford.


OUR ADVISORS

Steered by an exemplary team of internationally recognised clinicians and
scientists, and chaired by Sir John Bell (Regius Professor of Medicine
University of Oxford), our Scientific Advisory Board comprises – Prof. Chas
Bountra (Oxford), Prof. Johann DeBono (London), Prof. William Gallagher
(Dublin), Prof. Steve Jackson (Cambridge), Prof. Peter Johnson (Southampton),
Prof. David Kerr (Oxford), Prof. Michael O’Dwyer (Galway), Dr. Anthony Quinn
(Boston), & Prof. John Robertson (Nottingham).


OUR NAME

Carrick Therapeutics’ aim is to create the leading European based oncology
company. The name Carrick means ‘rock’ in Irish to emphasize our strong
foundation of like-minded scientists, collaborators and investors, and the
vision to build a durable world-class company. Carrick Therapeutics has an
ambitious patient focused vision to serve cancer patients around the world by
the introduction of ground breaking cancer therapies that will transform the way
cancer is treated.


OUR INVESTORS

We are backed by some of the most eminent providers of early stage capital,
including ARCH Ventures, Cambridge Enterprise, Rosetta Capital, Cambridge
Innovation Capital, Evotec, Google Ventures, and Lightstone Ventures, all of
whom have impeccable track records of accelerating the development of cutting
edge science into new therapies.




 * 0
 * 1
 * 2
 * 3
 * 4
 * 5
 * 6
 * 7
 * 8

hello@carricktherapeutics.com

NovaUCD
Belfield Innovation Park
University College Dublin
Belfield
Dublin 4

Magdalen Centre
Robert Robinson Avenue
The Oxford Science Park
Oxford
OX4 4GA

© 2016 Carrick Therapeutics



By continuing to use the site, you agree to the use of cookies. more information
Accept

The cookie settings on this website are set to "allow cookies" to give you the
best browsing experience possible. If you continue to use this website without
changing your cookie settings or you click "Accept" below then you are
consenting to this.

Close